^
    1d
    KSQ-4279-1101: A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=116, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed | N=250 --> 116
    Trial completion • Enrollment change
    |
    Lynparza (olaparib) • carboplatin • KSQ-4279
    1d
    Targeting CDK12 rescues C/EBPβ-mediated platinum and PARP inhibitor resistance in ovarian cancer. (PubMed, Cell Signal)
    Elevated C/EBPβ expression enhanced cisplatin resistance and olaparib resistance. Targeting C/EBPβ via CDK12 inhibition could rescue drug responsiveness of ovarian cancer, thereby counteracting platinum and PARP inhibitor resistance. C/EBPβ could thus be exploited as a candidate prognostic biomarker in ovarian cancer.
    Journal • PARP Biomarker
    |
    CDK12 (Cyclin dependent kinase 12)
    |
    Lynparza (olaparib) • cisplatin
    1d
    Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial (clinicaltrials.gov)
    P1/2, N=63, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date • Tumor mutational burden
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • etoposide IV
    3d
    Poly (ADP-ribose) polymerase inhibitor combination therapy in metastatic castration-resistant prostate cancer (PubMed, Urologie)
    PARPi + NHA represent a significant advance in mCRPC therapy. Molecular genetic testing for HRR mutations, especially BRCA 1/2, is crucial for treatment planning.
    Review • Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Lynparza (olaparib) • docetaxel • Talzenna (talazoparib) • Zejula (niraparib) • Xtandi (enzalutamide) • abiraterone acetate
    4d
    Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, AHS Cancer Control Alberta | Trial primary completion date: Jul 2027 --> Apr 2028
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • MGMT (6-O-methylguanine-DNA methyltransferase) • BRCA (Breast cancer early onset)
    |
    Lynparza (olaparib) • temozolomide
    8d
    MULTISARC: Molecular Profiling of Advanced Soft-tissue Sarcomas (clinicaltrials.gov)
    P3, N=603, Active, not recruiting, Institut National de la Santé Et de la Recherche Médicale, France | Trial completion date: Oct 2025 --> Jan 2026
    Trial completion date • IO biomarker
    |
    Lynparza (olaparib) • Mekinist (trametinib) • Ibrance (palbociclib) • Tafinlar (dabrafenib) • Imfinzi (durvalumab) • lapatinib • Zykadia (ceritinib) • Tasigna (nilotinib) • Lytgobi (futibatinib) • Tabrecta (capmatinib) • Daurismo (glasdegib)
    8d
    Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer. (PubMed, Ann Oncol)
    DUO-O met its primary PFS endpoints for first-line durvalumab plus carboplatin/paclitaxel and bevacizumab followed by durvalumab, bevacizumab plus olaparib maintenance versus carboplatin/paclitaxel and bevacizumab followed by bevacizumab in the non-tBRCAm HRD-positive and non-tBRCAm ITT populations. Further insight into long-term benefit is anticipated with additional follow-up.
    Journal • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    HRD • BRCA mutation
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel
    8d
    Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Hebei Medical University Fourth Hospital | Trial completion date: Sep 2024 --> Sep 2031 | Trial primary completion date: Sep 2023 --> Sep 2030
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    HER-2 negative
    |
    Lynparza (olaparib)
    9d
    SLX1 Inhibition Enhances Olaparib Sensitivity by Impairing Homologous Recombination Repair in Breast Cancer. (PubMed, Int J Mol Sci)
    In vivo, SLX1 knockdown synergizes with Olaparib to suppress tumor growth in xenograft models. These findings establish SLX1 as a critical regulator of HR function in BRCA1-proficient breast cancer and a promising target for restoring PARP inhibitor sensitivity through induced HR deficiency.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • HRD (Homologous Recombination Deficiency) • RAD51 (RAD51 Homolog A)
    |
    Lynparza (olaparib)
    9d
    The PIK3CA/AKT pathway drives therapy resistance in rhabdomyosarcoma. (PubMed, Nat Commun)
    Olaparib and temozolomide (OT) combination therapy is in clinical trial evaluation for rhabdomyosarcoma (RMS). The combination of OT + alpelisib also kills RMS cells which are resistant to standard-of-care combination chemotherapy and was effective in preclinical xenograft mouse models at curbing tumor growth. Our work defines a common resistance pathway in RMS and has credentialled PIK3CA/AKT inhibition as a preclinical strategy to kill therapy resistant RMS.
    Journal • PARP Biomarker
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    PIK3CA mutation
    |
    Lynparza (olaparib) • temozolomide • Piqray (alpelisib)
    9d
    Molecularly guided precision therapy in metastatic adamantinoma: a case report. (PubMed, Per Med)
    She showed a sustained clinical response to fourth-line treatment with the PARP inhibitor olaparib, which lasted 15 months and led to improved performance status. Subsequent progression led to combination therapy with atezolizumab and bevacizumab, maintaining stable disease for eight months. Molecularly guided treatment resulted in an overall survival of 25 months.
    Journal • PARP Biomarker • PD(L)-1 Biomarker
    |
    XRCC2 (X-Ray Repair Cross Complementing 2)
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • Tecentriq (atezolizumab)